Evonik Stock: A Market Divided Ahead of Crucial Earnings

Evonik shares defy analyst warnings with a 30% YTD surge. Key drivers include sector recovery, insider buying, and a favorable risk profile. Q1 results on May 8 are critical.

The shares of German specialty chemicals group Evonik have surged nearly 30% since the start of the year, a rally that defies the deep uncertainty brewing among analysts. As the company approaches its first-quarter report on May 8, the investment community is starkly polarized, with price targets ranging from bullish optimism to stark warnings.

This divergence is highlighted by recent analyst calls. On the pessimistic end, Jefferies rates the stock 'Underperform' with a target of €12.20, while Berenberg advises 'Sell' with a €14.00 target. Deutsche Bank, forecasting a significant 18% year-on-year drop in Q1 EBITDA to €461 million, maintains a 'Hold' and a €15.00 target. Conversely, Goldman Sachs holds a 'Buy' rating with a €20.00 target, and Warburg Research sets the highest bar at €20.40 per share.

The recent share price strength, closing at €17.31 last Friday and trading well above its 200-day moving average of €14.83, has been supported by several factors. A broad recovery rally in the European chemicals sector provided a tailwind. Internally, a show of confidence came from the boardroom: Executive Board member Dr. Claudine Mollenkopf purchased approximately 3,600 shares at an average price of €16.50 in late March. Furthermore, CEO Christian Kullmann's recent decision to retract his prior criticism of the European CO2 trading scheme has led to a market reassessment of political risks.

However, the company is not operating in a vacuum. The chemical industry faces significant headwinds, including an oil price shock—up around 50% since pre-conflict levels following the Iran crisis in late February—which pressures raw material costs. While Evonik is exposed, its risk profile is notably cushioned. Approximately 80% of its energy needs are secured via long-term contracts, insulating it from gas price volatility more than peers like BASF or Lanxess. Geographically, about 80% of products sold in the US are manufactured locally, shielding roughly 30% of group sales from potential new tariff burdens.

Intriguingly, one product line is turning a global crisis into an opportunity. Supply disruptions in Asia are tightening the market for the feed additive methionine, driving prices higher in both China and Europe. As a major producer, Evonik stands to gain from this dynamic shift, providing a counterweight to broader sector pressures.

All eyes are now on the Q1 figures to validate the stock's recent performance. Should the anticipated profit decline materialize, the immediate focus will shift to management's outlook for the second half of the year. The company has maintained its full-year 2026 guidance for adjusted EBITDA between €1.7 billion and €2.0 billion. Notably, Barclays recently revised its negative price assumptions and lifted its 2026 EBITDA estimate to €1.89 billion, placing it 3% above market consensus.

Beyond earnings, key corporate events loom. The virtual Annual General Meeting in Essen on June 3 will address two critical items: the dividend proposal of €1.00 per share for 2025 and the still-vacant CFO position, which has been open since September 2025. Looking ahead, a new dividend policy from 2026 onwards, targeting a payout ratio of 40-60% of adjusted net income, implies a yield of around 7% at current share prices—a potential safety net for investors.

Simultaneously, the "Evonik Tailor Made" transformation program continues its course, aiming for annual savings of €400 million and the reduction of up to 2,000 positions globally by the end of 2026. The upcoming quarterly report will be the first concrete test of whether the company's strategic defenses and specific advantages can support its elevated valuation amidst a deeply divided market sentiment.